

Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 November 2017

Cumulative for August, September, October
and November 2017



Contents

Summary of decisions effective 1 November 2017	3
Section H changes to Part II	5
Index	19

Summary of decisions

EFFECTIVE 1 NOVEMBER 2017

- Allopurinol (DP-Allopurinol) tab 100 mg and 300 mg – new listing and addition of HSS
- Allopurinol (Allopurinol-Apotex) tab 100 mg and 300 mg – to be delisted 1 January 2018
- Amino acid formula (e.g. Neocate Junior Unflavoured) powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g can – new listing of example brand
- Amino acid formula (Neocate Junior Vanilla) powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can – new listing
- Amino acid formula (e.g. Neocate Advance) powder 14 g protein, 50 g carbohydrate and 24.3 g fat per 100 g, 400 g can – to be delisted 1 January 2018
- Amino acid formula (Neocate Advance (Vanilla)) powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can – to be delisted 1 January 2018
- Anastrozole (Rolin) tab 1 mg – new listing and addition of HSS
- Anastrozole (Aremed and DP-Anastrozole) tab 1 mg – to be delisted 1 January 2018
- Betamethasone valerate with sodium fusidate [fusidic acid] crm 0.1% with sodium fusidate (fusidic acid) 2% - amended chemical name and presentation description
- Ceftazidime (Ceftazidime Mylan) inj 1 g vial – new listing
- Ceftazidime (Fortum) inj 500 mg, 1 g and 2 g vial – to be delisted 1 March 2018
- Cefuroxime (Cefuroxime Actavis) inj 750 mg and 1.5 g vial – new listing and addition of HSS
- Cefuroxime (Zinacef) inj 750 mg and 1.5 g vial – to be delisted 1 February 2018
- Clotrimazole (Clomazol) crm 1% – price increase and addition of HSS
- Dexamethasone (Ozurdex) ocular implant 700 mcg – new listing
- Ethinyloestradiol with levonorgestrel tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets (Microgynon 20 ED) and tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets (Levlen ED) – new listing and addition of HSS
- Ethinyloestradiol with levonorgestrel tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets (Ava 20 ED) and tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets (Ava 30 ED) – to be delisted 1 January 2018

Summary of decisions – effective 1 November 2017 (continued)

- Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride (Molaxole) powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – new listing and addition of HSS
- Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride (Lax-Sachets) powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – to be delisted 1 February 2018
- Metoclopramide hydrochloride (Metoclopramide Actavis 10) tab 10 mg – new listing and addition of HSS
- Metoclopramide hydrochloride (Metamide) tab 10 mg – to be delisted 1 January 2018
- Metolazone tab 5 mg – amended restriction
- Miconazole nitrate (Multichem) crm 2% – price increase and addition of HSS
- Minoxidil (Loniten) tab 10 mg – restriction removed
- Paclitaxel (Paclitaxel Ebewe) inj 6 mg per ml, 100 ml vial – to be delisted 1 April 2018
- Pemetrexed (Juno Pemetrexed) inj 100 mg and 500 mg vial – new listing
- Pyridoxine hydrochloride (Vitamin B6 25) tab 25 mg – price increase and addition of HSS
- Simvastatin (Simvastatin Mylan) tab 10 mg, 20 mg, 40 mg and 80 mg – new listing and addition of HSS
- Simvastatin (Arrow-Simva) tab 10 mg, 20 mg, 40 mg and 80 mg – to be delisted 1 January 2018
- Sodium cromoglicate cap 100 mg; nasal spray 4%; aerosol inhaler 5 mg per dose and eye drops 2% - amended chemical name
- Sodium fusidate [fusidic acid] crm 2% (DP Fusidic Acid Cream); oint 2% (Foban); tab 250 mg (Fucidin) and eye drops 1% (Fucithalamic) – amended chemical name
- Terbinafine (Deolate) tab 250 mg – new listing and addition of HSS
- Terbinafine (Dr Reddy's Terbinafine) tab 250 mg – to be delisted 1 January 2018
- Testosterone cipionate (Depo-Testosterone) inj 100 mg per ml, 10 ml vial – amended chemical name
- Travoprost (Travopt) eye drops 0.004% – new listing and addition of HSS

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 November 2017

ALIMENTARY TRACT AND METABOLISM

14	SODIUM CROMOGLICATE CROMOGLYCATE (amended chemical name) Cap 100 mg			
20	MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE (brand change) → Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – 1% DV Feb-18 to 2020	6.78	30	Molaxole
	Note – Lax-Sachets powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg to be delisted from 1 February 2018.			
27	PYRIDOXINE HYDROCHLORIDE (↑ price and addition of HSS) Tab 25 mg – 1% DV Jan-18 to 2020	2.70	90	Vitamin B6 25

CARDIOVASCULAR SYSTEM

48	METOLAZONE (amended restriction) → Tab 5 mg Restricted Initiation Either Any of the following: 1 Patient has refractory heart failure and is intolerant or has not responded to loop diuretics and/or loop-thiazide combination therapy; or 2 Patient has severe refractory nephrotic oedema unresponsive to high dose loop diuretics and concentrated albumin infusions; or 3 Paediatric patient has oedema secondary to nephrotic syndrome that has not responded to loop diuretics.			
49	SIMVASTATIN (brand change) Tab 10 mg – 1% DV Jan-18 to 2020	0.95	90	Simavastatin Mylan
	Tab 20 mg – 1% DV Jan-18 to 2020	1.52	90	Simavastatin Mylan
	Tab 40 mg – 1% DV Jan-18 to 2020	2.63	90	Simavastatin Mylan
	Tab 80 mg – 1% DV Jan-18 to 2020	6.00	90	Simavastatin Mylan
	Note – Arrow-Simva tab 10 mg, 20 mg, 40 mg and 80 mg to be delisted from 1 January 2018.			
52	MINOXIDIL (restriction removed) Tab 10 mg	70.00	100	Loniten
	Restricted Initiation For patients with severe refractory hypertension who have failed to respond to extensive multiple therapies			

DERMATOLOGICALS

55	SODIUM FUSIDATE [FUSIDIC ACID] (amended chemical name) Crm 2%	2.52	15 g	DP Fusidic Acid Cream
	Oint 2%	3.45	15 g	Foban

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2017 (continued)

55	CLOTRIMAZOLE (↑ price and addition of HSS) Crn 1% – 1% DV Jan-18 to 2020	0.70	20 g	Clomazol
55	MICONAZOLE NITRATE (↑ price and addition of HSS) Crn 2% – 1% DV Jan-18 to 2020	0.74	15 g	Multichem
59	BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUSIDIC ACID] (amended chemical name and presentation) Crn 0.1% with sodium fusidate (fusidic acid) 2%			

GENITO-URINARY SYSTEM

61	ETHINYLOESTRADIOL WITH LEVONORGESTREL (brand change) Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets – 1% DV Jan-18 to 2020	2.18	84	Microgynon 20 ED
	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets – 1% DV Jan-18 to 2020	1.77	84	Levlen ED
	Note – Ava 20 ED tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets and Ava 30 ED tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets to be delisted from 1 January 2018.			

HORMONE PREPARATIONS

66	TESTOSTERONE CIPIONATE CYPIONATE (amended chemical name) Inj 100 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020	76.50	1	Depo-Testosterone
----	---	-------	---	--------------------------

INFECTIONS

77	CEFUROXIME (brand change) Inj 750 mg vial – 1% DV Feb-18 to 2020	9.85	10	Cefuroxime Actavis
	Inj 1.5 g vial – 1% DV Feb-18 to 2020	14.36	10	Cefuroxime Actavis
	Note – Zinacef inj 750 mg and 1.5 g vials to be delisted from 1 February 2018.			
77	CEFTAZIDIME (brand change) → Inj 1 g vial	23.00	5	Ceftazidime Mylan
	Note – Fortum inj 1 g vial to be delisted from 1 March 2018.			
77	CEFTAZIDIME (delisting) → Inj 500 mg vial	5.30	1	Fortum
	→ Inj 2 g vial	3.34	1	Fortum
	Note – Fortum inj 500 mg and 2 g vials to be delisted from 1 March 2018.			
83	SODIUM FUSIDATE [FUSIDIC ACID] (amended chemical name) → Tab 250 mg – 1% DV Jun-17 to 2020	34.50	12	Fucidin
86	TERBINAFINE (brand change) Tab 250 mg – 1% DV Jan-18 to 2020	1.33	14	Deolate
	Note – Dr Reddy's Terbinafine tab 250 mg to be delisted from 1 January 2018.			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

Changes to Section H Part II – effective 1 November 2017 (continued)

MUSCULOSKELETAL SYSTEM

104	ALLOPURINOL (brand change)			
	Tab 100 mg – 1% DV Jan-18 to 2020	4.54	500	DP-Allopurinol
	Tab 300 mg – 1% DV Jan-18 to 2020	10.35	500	DP-Allopurinol
	Note – Allopurinol-Apotex tab 100 mg and 300 mg to be delisted from 1 January 2018.			

NERVOUS SYSTEM

123	METOCLOPRAMIDE HYDROCHLORIDE (brand change)			
	Tab 10 mg – 1% DV Jan-18 to 2020	1.30	100	Metoclopramide Actavis 10
	Note – Metamide tab 10 mg to be delisted from 1 January 2018.			

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

139	PEMETREXED (new listing)			
	→ Inj 100 mg vial – 1% DV Jan-18 to 2019	60.89	1	Juno Pemetrexed
	→ Inj 500 mg vial – 1% DV Jan-18 to 2019	217.77	1	Juno Pemetrexed
	Restricted			
	Initiation – Mesothelioma			
	<i>Re-assessment required after 8 months</i>			
	Both:			
	1 Patient has been diagnosed with mesothelioma; and			
	2 Pemetrexed to be administered at a dose of 500 mg/m ² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.			
	Continuation – Mesothelioma			
	<i>Re-assessment required after 8 months</i>			
	All of the following:			
	1 No evidence of disease progression; and			
	2 The treatment remains appropriate and the patient is benefitting from treatment; and			
	3 Pemetrexed to be administered at a dose of 500mg/m ² every 21 days for a maximum of 6 cycles.			
	Initiation – Non small cell lung cancer			
	<i>Re-assessment required after 8 months</i>			
	Both:			
	1 Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and			
	2 Either:			
	2.1 Both:			
	2.1.1 Patient has chemotherapy-naïve disease; and			
	2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m ² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles, or			
	2.2 All of the following:			
	2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and			
	2.2.2 Patient has not received prior funded treatment with pemetrexed; and			
	2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m ² every 21 days for a maximum of 6 cycles.			

continued...

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2017 (continued)

continued...

Continuation – Non small cell lung cancer

Re-assessment required after 8 months

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment; and
- 3 Pemetrexed is to be administered at a dose of 500mg/m² every 21 days.

147	PACLITAXEL (delisting) Inj 6 mg per ml, 100 ml vial.....	73.06	1	Paclitaxel Ebewe
	Note – Paclitaxel Ebewe inj 6 mg per ml, 100 ml vial to be delisted from 1 April 2018.			
150	ANASTROZOLE (brand change) Tab 1 mg – 1% DV Jan-18 to 2020	5.04	30	Rolin
	Note – Aremed and DP-Anastrozole tab 1 mg to be delisted 1 January 2018.			

RESPIRATORY SYSTEM AND ALLERGIES

190	SODIUM CROMOGLICATE GROMOGLYATE (amended chemical name) Nasal spray 4%			
194	SODIUM CROMOGLICATE GROMOGLYATE (amended chemical name) Aerosol inhaler 5 mg per dose			

SENSORY ORGANS

196	SODIUM FUSIDATE [FUSIDIC ACID] (amended chemical name) Eye drops 1%.....	4.50	5 g	Fucithalmic
197	DEXAMETHASONE (new listing) ➔ Ocular implant 700 mcg.....	1,444.50	1	Ozurdex
	Restricted Initiation – Diabetic macular oedema Ophthalmologist <i>Limited to 12 months treatment</i> 1 Patients have diabetic macular oedema with pseudophakic lens; and 2 Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and 3 Either: 3.1 Patient's disease has progressed despite 3 injections with bevacizumab; or 3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF inhibitors; and 4 Dexamethasone implants are to be administered not more frequently than once every 4 months, and up to a maximum of 3 implants per year. Continuation – Diabetic macular oedema Ophthalmologist <i>Limited to 12 months treatment</i> Both: 1 Patient's vision is stable or has improved (prescriber determined); and 2 Dexamethasone implants are to be administered not more frequently than once every 4 months, and up to a maximum of 3 implants per year.			

continued...

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

Changes to Section H Part II – effective 1 November 2017 (continued)
continued...

Initiation – Women of child bearing age with diabetic macular oedema

Ophthalmologist

Limited to 12 months treatment

All of the following:

- 1 Patients have diabetic macular oedema; and
- 2 Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
- 3 Patient is of child bearing potential and has not yet completed a family; and
- 4 Dexamethasone implants are to be administered not more frequently than once every 4 months, and up to a maximum of 3 implants per year.

Continuation – Women of child bearing age with diabetic macular oedema

Ophthalmologist

Limited to 12 months treatment

All of the following:

- 1 Patient's vision is stable or has improved (prescriber determined); and
- 2 Patient is of child bearing potential and has not yet completed a family; and
- 3 Dexamethasone implants are to be administered not more frequently than once every 4 months, and up to a maximum of 3 implants per year.

197	SODIUM CROMOLGICATE CROMOLGICATE (amended chemical name) Eye drops 2%			
200	TRAVOPROST (new listing) Eye drops 0.004% – 1% DV Jan-18 to 2020	7.30	5 ml	Travopt

SPECIAL FOODS

221	AMINO ACID FORMULA (brand change) → Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g can			<i>e.g. Neocate Junior Unflavoured</i>
	Note – Neocate Advance powder 14 g protein, 50 g carbohydrate and 24.3 g fat per 100 g, 400 g can to be delisted from 1 January 2018			
221	AMINO ACID FORMULA (brand change) → Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can.....	53.00	400 g	Neocate Junior Vanilla
	Note – Neocate Advance (Vanilla) powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can to be delisted from 1 January 2018			

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 October 2017

ALIMENTARY TRACT AND METABOLISM

14	OLSALAZINE (new listing)			
	Tab 500 mg	93.37	100	Dipentum
	Cap 250 mg	53.00	100	Dipentum
15	HYOSCINE BUTYLBROMIDE (brand change)			
	Tab 10 mg – 1% DV Dec-17 to 2020	8.75	100	Buscopan
	Note – Gastrosoothe tab 10 mg to be delisted from 1 December 2017.			
26	MULTIVITAMIN RENAL (↓ price)			
	→ Cap	6.49	30	Clinicians Renal Vit

CARDIOVASCULAR SYSTEM

45	BISOPROLOL FUMARATE (pack size change and addition of HSS)			
	Tab 2.5 mg – 1% DV Dec-17 to 2020	3.53	90	Bosvate
	Tab 5 mg – 1% DV Dec-17 to 2020	5.15	90	Bosvate
	Tab 10 mg – 1% DV Dec-17 to 2020	9.40	90	Bosvate
	Note – This is a listing of a new pack size. Bosvate tab 2.5 mg, 5 mg and 10 mg, 30 tab pack to be delisted from 1 December 2017.			
45	CARVEDILOL (brand change)			
	Tab 6.25 mg – 1% DV Dec-17 to 2020	2.24	60	Carvedilol Sandoz
	Tab 12.5 mg – 1% DV Dec-17 to 2020	2.30	60	Carvedilol Sandoz
	Tab 25 mg – 1% DV Dec-17 to 2020	2.95	60	Carvedilol Sandoz
	Note – Dicarz tab 6.25 mg, 12.5 mg and 25 mg to be delisted from 1 December 2017.			
45	METOPROLOL SUCCINATE (brand change)			
	Tab long-acting 23.75 mg – 1% DV Mar-18 to 2020	1.03	30	Betaloc CR
	Tab long-acting 47.5 mg – 1% DV Mar-18 to 2020	1.25	30	Betaloc CR
	Tab long-acting 95 mg – 1% DV Mar-18 to 2020	1.99	30	Betaloc CR
	Tab long-acting 190 mg – 1% DV Mar-18 to 2020	3.00	30	Betaloc CR
	Note – Metoprolol - AFT CR tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg to be delisted from 1 March 2018.			
46	NIFEDIPINE (brand change)			
	Tab long-acting 30 mg – 1% DV Dec-17 to 2020	3.14	30	Adalat Oros
	Tab long-acting 60 mg – 1% DV Dec-17 to 2020	5.67	30	Adalat Oros
	Note – Adefin XL tab long-acting 30 mg and 60 mg to be delisted 1 December 2017.			

DERMATOLOGICALS

56	PERMETHRIN (↑ price and addition of HSS)			
	Crmm 5% – 1% DV Dec-17 to 2020	4.95	30 g	Lyderm
58	HYDROCORTISONE WITH PARAFFIN AND WOOL FAT (delisting)			
	Lotn 1% with paraffin liquid 15.9% and wool fat 0.6%			
	Note – Hydrocortisone with paraffin and wool fat lotn 1% with paraffin liquid 15.9% and wool fat 0.6% to be delisted from 1 October 2017.			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

Changes to Section H Part II – effective 1 October 2017 (continued)

60	CALCIUM GLUCONATE (new listing of example brand and delisting) Gel 2.5% Note – healthE gel 2.5% brand to be delisted from 1 April 2018.			<i>e.g Orion</i>
----	---	--	--	------------------

GENITO-URINARY SYSTEM

64	FINASTERIDE (brand change) → Tab 5 mg – 1% DV Dec-17 to 2020 4.81 Note – Finpro tab 5 mg to be delisted from 1 December 2017.	100		Ricit
----	---	-----	--	--------------

HORMONE PREPARATIONS

66	TESTOSTERONE (delisting) Patch 2.5 mg per day 80.00 Note – Androderm patch 2.5 mg per day to be delisted from 1 March 2018.	60		Androderm
----	---	----	--	-----------

NERVOUS SYSTEM

114	PARACETAMOL (↑ price and addition of HSS) Oral liq 120 mg per 5 ml – 1% DV Dec-17 to 2020 5.35 Note – Air Flow Products tab 10 mg and 20 mg to be delisted from 1 December 2017.	1,000 ml		Paracare
118	ESCITALOPRAM (brand change) Tab 10 mg – 1% DV Dec-17 to 2020 1.11 Tab 20 mg – 1% DV Dec-17 to 2020 1.90 Note – Air Flow Products tab 10 mg and 20 mg to be delisted from 1 December 2017.	28		Apo-Escitalopram Apo-Escitalopram
120	LAMOTRIGINE (delisting) Tab dispersible 25 mg 14.74 Tab dispersible 50 mg 24.73 Tab dispersible 100 mg 42.34 Note – Motrig tab dispersible 25 mg, 50 mg and 100 mg to be delisted from 1 April 2018.	56		Motrig Motrig Motrig
126	RISPERIDONE (↓ price and addition of HSS) Tab 0.5 mg – 1% DV Dec-17 to 2020 1.86 Tab 1 mg – 1% DV Dec-17 to 2020 2.06 Tab 2 mg – 1% DV Dec-17 to 2020 2.29 Tab 3 mg – 1% DV Dec-17 to 2020 2.50 Tab 4 mg – 1% DV Dec-17 to 2020 3.43	60		Actavis Actavis Actavis Actavis Actavis

VARIOUS

206	GADOBUTROL (new listing) Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 5 ml prefilled syringe 120.00	5		Gadovist
-----	--	---	--	----------

		Price (ex man. Excl. GST)		Brand or Generic Manufacturer
		\$	Per	

Changes to Section H Part II – effective 21 September 2017

INFECTIONS

80	AMOXICILLIN (new listing) Grans for oral liq 250 mg per 5 ml	1.31	100 ml	Alphamox 250
----	---	------	--------	--------------

Effective 1 September 2017

ALIMENTARY TRACT AND METABOLISM

18	METFORMIN HYDROCHLORIDE (delisting) Tab immediate-release 850 mg.....	7.82	500	Apotex
	Note – Apotex tab immediate-release 850 mg to be delisted from 1 February 2018.			

BLOOD AND BLOOD FORMING ORGANS

34	ENOXAPARIN SODIUM (↓ price)			
	Inj 20 mg in 0.2 ml syringe	27.93	10	Clexane
	Inj 40 mg in 0.4 ml syringe	37.27	10	Clexane
	Inj 60 mg in 0.6 ml syringe	56.18	10	Clexane
	Inj 80 mg in 0.8 ml syringe	74.90	10	Clexane
	Inj 100 mg in 1 ml syringe	93.80	10	Clexane
	Inj 120 mg in 0.8 ml syringe	116.55	10	Clexane
	Inj 150 mg in 1 ml syringe	133.20	10	Clexane
40	SODIUM CHLORIDE (HSS suspended) Inj 0.9%, 5 ml ampoule			
	– 1% DV Mar-17 to 2019 31 Aug 2017	7.00	50	InterPharma

CARDIOVASCULAR SYSTEM

43	LOSARTAN POTASSIUM (↓ price and addition of HSS)			
	Tab 12.5 mg – 1% DV Nov-17 to 2020	1.39	84	Losartan Actavis
	Tab 25 mg – 1% DV Nov-17 to 2020	1.63	84	Losartan Actavis
	Tab 50 mg – 1% DV Nov-17 to 2020	2.00	84	Losartan Actavis
	Tab 100 mg – 1% DV Nov-17 to 2020	2.31	84	Losartan Actavis
46	PROPRANOLOL (new listing)			
	Tab 10 mg	3.65	100	Apo-Propranolol
	Tab 40 mg	4.65	100	Apo-Propranolol
	Note – This is the listing of new Pharmacodes for Apo-Propranolol tab 10 mg, 2525941 and 40 mg, 2525968.			

DERMATOLOGICALS

56	ZINC AND CASTOR OIL (↓ price and addition of HSS) Oint, BP – 1% DV Nov-17 to 2020	1.26	20 g	healthE
----	--	------	------	---------



(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2017 (continued)

GENITO-URINARY SYSTEM

63	ERGOMETRINE MALEATE (↑ price and addition of HSS) Inj 500 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020	105.00	5	DBL Ergometrine
----	---	--------	---	-----------------

INFECTIONS

80	PIPERACILLIN WITH TAZOBACTAM (delisting) → Inj 4 g with tazobactam 0.5 g vial	5.84	1	Hospira Note – Hospira inj 4 g with tazobactam 0.5 g vial to be delisted from 1 January 2018.
96	OSELTAMIVIR (additional note) Note: The restriction on the use of oseltamivir to hospitalised patients means that supply into the community under Rule 8 of Section H is not permitted. → Tab 75 mg → Powder for oral suspension 6 mg per ml			
96	ZANAMIVIR (additional note) Note: The restriction on the use of zanamivir to hospitalised patients means that supply into the community under Rule 8 of Section H is not permitted. → Powder for inhalation 5 mg	37.38	20 dose	Relenza Rotadisk

MUSCULOSKELETAL SYSTEM

99	NEOSTIGMINE METILSULFATE (addition of HSS) Inj 2.5 mg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020	98.00	50	AstraZeneca
106	SUXAMETHONIUM CHLORIDE (addition of HSS) Inj 50 mg per ml, 2 ml ampoule – 1% DV Nov-17 to 2020	78.00	50	AstraZeneca

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

149	OCTREOTIDE (↑ price, amended brand name and addition of HSS) Inj 50 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020	30.64	5	DBL Octreotide
149	OCTREOTIDE (↓ price, amended brand name and addition of HSS) Inj 100 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020	18.69	5	DBL Octreotide
	Inj 500 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020	72.50	5	DBL Octreotide

RESPIRATORY SYSTEM AND ALLERGIES

193	FLUTICASONE (↓ price) Aerosol inhaler 50 mcg per dose	4.68	120 dose	Floair
	Aerosol inhaler 125 mcg per dose	7.22	120 dose	Floair
	Aerosol inhaler 250 mcg per dose	10.18	120 dose	Floair

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2017 (continued)

194	SALMETEROL (↓ price) Aerosol inhaler 25 mcg per dose	9.90	120 dose	Meterol
194	FLUTICASONE WITH SALMETEROL (↓ price) Aerosol inhaler 50 mcg with salmeterol 25 mcg	14.58	120 dose	RexAir
	Aerosol inhaler 125 mcg with salmeterol 25 mcg	16.83	120 dose	RexAir
195	AMINOPHYLLINE (↑ price and addition of HSS) Inj 25 mg per ml, 10 ml ampoule – 1% DV Nov-17 to 2020	124.37	5	DBL Aminophylline

SENSORY ORGANS

197	PREDNISOLONE ACETATE (HSS suspended) Eye drops 1% – 1% DV Jan-17 to 2019 31 Aug 2017	3.93	10 ml	Prednisolone- AFT
-----	---	------	-------	-------------------

PART III - OPTIONAL PHARMACEUTICALS

237	SODIUM NITROPRUSSIDE (new listing) Test strip	12.00	50 strip	Ketostix
237	SODIUM NITROPRUSSIDE (delisting) Test strip	6.00	50 strip	Accu-Chek Ketur-Test
	Note – Accu-Chek Ketur-Test, test strips to be delisted from 1 March 2018.			

Effective 1 August 2017

ALIMENTARY TRACT AND METABOLISM

15	RANITIDINE (↑ price and addition of HSS) Tab 150 mg – 1% DV Oct-17 to 2020	12.91	500	Ranitidine Relief
	Tab 300 mg – 1% DV Oct-17 to 2020	18.21	500	Ranitidine Relief
	Oral liq 150 mg per 10 ml – 1% DV Oct-17 to 2020	5.14	300 ml	Peptisoothe
19	ISPAGHULA (PSYLLIUM) HUSK (↑ price and addition of HSS) Powder for oral soln – 1% DV Oct-17 to 2020	6.05	500 g	Konsyl-D
25	NYSTATIN (brand change) Oral liquid 100,000 u per ml – 1% DV Oct-17 to 2020	1.95	24 ml	Nilstat
	Note – m-Nystatin oral liquid 100,000 u per ml to be delisted from 1 October 2017.			
27	PYRIDOXINE HYDROCHLORIDE (↑ price and addition of HSS) Tab 50 mg – 1% DV Oct-17 to 2020	13.63	500	Apo-Pyridoxine
27	COLECALCIFEROL (↓ price and addition of HSS) Cap 1.25 mg (50,000 iu) – 1% DV Oct-17 to 2020	2.50	12	Vit.D3



(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2017 (continued)

BLOOD AND BLOOD FORMING ORGANS

35	TRISODIUM CITRATE CITRATE SODIUM (amended chemical name and presentation) Inj 4% (200 mg per 5 ml), 5 ml ampoule Inj 46.7% (2.36 g per 5 ml), 5 ml ampoule Inj 46.7% (1.4 g per 3 ml), 3 ml syringe			
38	GLUCOSE [DEXTROSE] (addition of HSS) Inj 50%, 10 ml ampoule – 1% DV Oct-17 to 2020 (↑ price).....	29.50	5	Biomed
	Inj 50%, 90 ml bottle – 1% DV Oct-17 to 2020	14.50	1	Biomed

CARDIOVASCULAR SYSTEM

45	BISOPROLOL FUMARATE (↓ price) Tab 2.5 mg 1.18 Tab 5 mg 1.72 Tab 10 mg 3.13		30 30 30	Bosvate Bosvate Bosvate
50	NICOTINIC ACID (↑ price and addition of HSS) Tab 50 mg – 1% DV Oct-17 to 2020 4.12 Tab 500 mg – 1% DV Oct-17 to 2020 17.89		100 100	Apo-Nicotinic Acid Apo-Nicotinic Acid
50	ISOSORBIDE MONONITRATE (↑ price and addition of HSS) Tab 20 mg – 1% DV Oct-17 to 2020 18.80		100	Ismo-20

DERMATOLOGICALS

55	SULPHADIAZINE SILVER SULFADIAZINE SILVER (amended chemical name) Crm 1% – 1% DV Aug-17 to 2020 10.80		50 g	Flamazine
56	PERMETHRIN (↑ price and addition of HSS) Lotn 5% – 1% DV Oct-17 to 2020 3.69		30 ml	A-Scabies
57	EMULSIFYING OINTMENT (addition of HSS) Oint BP – 1% DV Oct-17 to 2020 1.84 Note: DV limit applies to pack sizes of less than 200 g. Oint BP, 500 g – 1% DV Oct-17 to 2020 (↑ price)..... 3.59 Note: DV limit applies to pack sizes of greater than 200 g.		100 g 500 g	Jaychem AFT
59	PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCEIN (↑ price and addition of HSS) Soln 2.3% with trolamine laurilsulfate and fluorescein sodium – 1% DV Oct-17 to 2020 3.86 Note – Pinetarsol soln 2.3% with trolamine laurilsulfate and fluorescein, 1,000 ml pack to be delisted from 1 October 2017.		500 ml	Pinetarsol

GENITO-URINARY SYSTEM

63	OESTRIOL (new listing and addition of HSS) Crm 1 mg per g with applicator – 1% DV Oct-17 to 2020 6.62 Pessaries 500 mcg – 1% DV Oct-17 to 2020 6.86		15 g 15	Ovestin Ovestin
----	---	--	------------	----------------------------------

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2017 (continued)

HORMONE PREPARATIONS

67	DEXAMETHASONE PHOSPHATE (delisting) Inj 4 mg per ml, 2 ml ampoule – 1% DV Jul-16 to 2019	12.59	5	Max Health
Note – Max Health inj 4 mg per ml, 2 ml ampoule, 5 inj pack to be delisted from 1 September 2017. The 10 inj pack size remains listed.				
75	DESMOPRESSIN ACETATE (↑ price and addition of HSS) Nasal spray 10 mcg per dose – 1% DV Oct-17 to 2020	23.95	6 ml	Desmopressin-PH&T

INFECTIONS

79	CLARITHROMYCIN (new listing) → Inj 500 mg vial	12.04	1	Klacid
79	CLARITHROMYCIN (HSS delayed and ↓ price) → Inj 500 mg vial – 1% DV Sep-17 to 2020	12.04	1	Martindale
80	AMOXICILLIN WITH CLAVULANIC ACID (↓ price and addition of HSS) Tab 500 mg with clavulanic acid 125 mg – 1% DV Oct-17 to 2020	1.88	20	Augmentin
82	AZTREONAM (↑ price) → Inj 1 g vial	182.46	5	Azactam
83	TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE] (↑ price and addition of HSS) Oral liq 8 mg with sulphamethoxazole 40 mg per ml – 1% DV Oct-17 to 2020	2.97	100 ml	Deprim
97	PEGYLATED INTERFERON ALFA-2A (↓ price and addition of HSS) → Inj 180 mcg prefilled syringe – 1% DV Oct-17 to 2020	500.00	4	Pegasys
97	PEGYLATED INTERFERON ALFA-2A (delisting delayed) → Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112)	1,159.84	1	Pegasys RBV Combination Pack
Note – Pegasys RBV Combination Pack inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) delist delayed until further notice.				

MUSCULOSKELETAL SYSTEM

107	CELECOXIB (amended restriction) Note – The DV limit of 1% applies to the celecoxib chemical rather than each individual line item. Cap 100 mg – 1% DV Aug-17 to 2020	3.63	60	Celecoxib Pfizer
	Cap 200 mg – 1% DV Aug-17 to 2020	2.30	30	Celecoxib Pfizer
Restricted Initiation For preoperative and/or postoperative use for a total of up to 8 days' use.				

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2017 (continued)

107	ETORICOXIB (amended restriction) → Tab 30 mg → Tab 60 mg → Tab 90 mg → Tab 120 mg Restricted Initiation For preoperative and/or postoperative use for a total of up to 8 days' use. For in-vivo investigation of allergy only.			
108	NAPROXEN (delisting) Tab long-acting 750 mg – 1% DV Jun-15 to 2018 18.00 Tab long-acting 1 g – 1% DV Jun-15 to 2018 21.00 Note – Naprosyn SR 750 tab long-acting 750 mg and Naprosyn SR 1000 tab long-acting 1 g, 90 tab pack to be delisted from 1 October 2017. The 28 tab pack remains listed.	90 90	Naprosyn SR 750 Naprosyn SR 1000	

NERVOUS SYSTEM

112	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (brand change and amended presentation description) Oral (viscous gel) soln 2% – 1% DV Oct-17 to 2020 38.00 Note – Xylocaine Viscous oral (gel) soln 2% to be delisted from 1 October 2017.	200 ml	Mucosoothe	
114	FENTANYL (addition of HSS) Patch 12.5 mcg per hour – 1% DV Oct-17 to 2020 (↑ price) 2.95 Patch 25 mcg per hour – 1% DV Oct-17 to 2020 3.66 Patch 50 mcg per hour – 1% DV Oct-17 to 2020 (↑ price) 6.65 Patch 75 mcg per hour – 1% DV Oct-17 to 2020 (↑ price) 9.25 Patch 100 mcg per hour – 1% DV Oct-17 to 2020 (↑ price) 11.40	5 5 5 5 5	Fentanyl Sandoz Fentanyl Sandoz Fentanyl Sandoz Fentanyl Sandoz Fentanyl Sandoz	
115	MORPHINE SULPHATE (pack size change and addition of HSS) Inj 1 mg per ml, 100 ml bag – 1% DV Oct-17 to 2020 97.25 Inj 1 mg per ml, 10 ml syringe – 1% DV Oct-17 to 2020 24.00 Inj 1 mg per ml, 50 ml syringe – 1% DV Oct-17 to 2020 50.75 Note – Biomed inj 1 mg per ml, 100 ml bag, 1 mg per ml, 10 ml syringe and 1 mg per ml, 50 ml syringe, 10 inj pack to be delisted from 1 October 2017.	5 5 5	Biomed Biomed Biomed	
116	REMIFENTANIL HYDROCHLORIDE (brand change and amended chemical name) Inj 1 mg vial – 1% DV Oct-17 to 2020 13.95 Inj 2 mg vial – 1% DV Oct-17 to 2020 19.95 Note – Ultiva inj 1 mg and 2 mg vial to be delisted from 1 October 2017.	5 5	Remifentanil-AFT Remifentanil-AFT	

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

144	IMATINIB MESILATE (↓ price and addition of HSS) Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule Cap 100 mg – 1% DV Oct-17 to 2020 98.00 Cap 400 mg – 1% DV Oct-17 to 2020 197.50	60 30	Imatinib-AFT Imatinib-AFT	
-----	---	----------	--	--

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2017 (continued)

147	PACLITAXEL (↑ price and addition of HSS)			
	Inj 6 mg per ml, 5 ml vial – 1% DV Oct-17 to 2020	47.30	5	Paclitaxel Ebewe
	Inj 6 mg per ml, 16.7 ml vial – 1% DV Oct-17 to 2020	20.00	1	Paclitaxel Ebewe
147	PACLITAXEL (↓ price and addition of HSS)			
	Inj 6 mg per ml, 50 ml vial – 1% DV Oct-17 to 2020	35.35	1	Paclitaxel Ebewe

RESPIRATORY SYSTEM AND ALLERGIES

190	IPRATROPIUM BROMIDE (↑ price and addition of HSS)			
	Aqueous nasal spray 0.03% – 1% DV Oct-17 to 2020	4.61	15 ml	Univent

Effective 1 July 2017

NERVOUS SYSTEM

116	MORPHINE SULPHATE (Pharmacode change)			
	Tab immediate-release 10 mg – 1% DV Sep-17 to 2020	2.80	10	Sevredol
	Tab immediate-release 20 mg – 1% DV Sep-17 to 2020	5.52	10	Sevredol

Note – this is a change from a bottle to blister pack (2520990 and 2521008 respectively). The bottle packs are to be delisted 1 October 2017.

Index

Pharmaceuticals and brands

A	
Accu-Chek Ketur-Test	14
Adalat Oros	10
Allopurinol	7
Alphamox 250	12
Amino acid formula	9
Aminophylline	14
Amoxicillin	12
Amoxicillin with clavulanic acid	16
Anastrozole	8
Androderm	11
Apo-Escitalopram	11
Apo-Nicotinic Acid	15
Apo-Propranolol	12
Apo-Pyridoxine	14
A-Scabies	15
Augmentin	16
Azactam	16
Aztreonam	16
B	
Betaloc CR	10
Betamethasone valerate with fusidic acid	6
Betamethasone valerate with sodium fusidate [fusidic acid]	6
Bisoprolol fumarate	10, 15
Bosvate	10, 15
Buscopan	10
C	
Calcium gluconate	11
Carvedilol	10
Carvedilol Sandoz	10
Ceftazidime	6
Ceftazidime Mylan	6
Cefuroxime	6
Cefuroxime Actavis	6
Celecoxib	16
Celecoxib Pfizer	16
Citrate sodium	15
Clarithromycin	16
Clexane	12
Clinicians Renal Vit	10
Clomazol	6
Clotrimazole	6
Colecalciferol	14
Co-trimoxazole	16
D	
DBL Aminophylline	14
DBL Ergometrine	13
DBL Octreotide	13
Deolate	6
Depo-Testosterone	6
Deprim	16
Desmopressin acetate	16
Desmopressin-PH&T	16
Dexamethasone	8
Dexamethasone phosphate	16
Dextrose	15
Dipentum	10
DP-Allopurinol	7
DP Fusidic Acid Cream	5
E	
Emulsifying ointment	15
Enoxaparin sodium	12
Ergometrine maleate	13
Escitalopram	11
Ethinylloestradiol with levonorgestrel	6
Etoricoxib	17
F	
Fentanyl	17
Fentanyl Sandoz	17
Finasteride	11
Flamazine	15
Floair	13
Fluticasone	13
Fluticasone with salmeterol	14
Foban	5
Fortum	6
Fucidin	6
Fucithalamic	8
Fusidic acid	5, 6, 8
G	
Gadobutrol	11
Gadovist	11
Glucose [dextrose]	15
H	
Hydrocortisone with paraffin and wool fat	10
Hyoscine butylbromide	10
I	
Imatinib-AFT	17
Imatinib mesilate	17
Ipratropium bromide	18
Ismo-20	15
Isosorbide mononitrate	15
Ispaghula (psyllium) husk	14
J	
Juno Pemetrexed	7
K	
Ketostix	14
Klacid	16
Konsyl-D	14
L	
Lamotrigine	11

Index

Pharmaceuticals and brands

Levlen ED	6	Peptisoothe.....	14
Lidocaine [lignocaine] hydrochloride	17	Permethrin	10, 15
Lignocaine	17	Pinetarsol.....	15
Loniten	5	Pine tar with trolamine laurilsulfate and fluorescein..	15
Losartan Actavis	12	Piperacillin with tazobactam	13
Losartan potassium.....	12	Prednisolone acetate	14
Lyderm	10	Prednisolone- AFT.....	14
M		Propranolol	12
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride.....	5	Pyridoxine hydrochloride	5, 14
Meterol	14	R	
Metformin hydrochloride	12	Ranitidine.....	14
Metoclopramide Actavis 10	7	Ranitidine Relief	14
Metoclopramide hydrochloride	7	Relenza Rotadisk	13
Metolazone	5	Remifentanil.....	17
Metoprolol succinate	10	Remifentanil-AFT.....	17
Miconazole nitrate	6	Remifentanil hydrochloride	17
Microgynon 20 ED	6	RexAir.....	14
Minoxidil	5	Ricit.....	11
Molaxole	5	Risperidone.....	11
Morphine sulphate.....	17, 18	Rolin.....	8
Motrig.....	11	S	
Mucosoothe.....	17	Salmeterol	14
Multivitamin renal	10	Sevredol	18
N		Simavastatin Mylan	5
Naprosyn SR 750.....	17	Simvastatin	5
Naprosyn SR 1000.....	17	Sodium chloride.....	12
Naproxen	17	Sodium cromoglicate	5, 8, 9
Neocate Junior Unflavoured.....	9	Sodium cromoglycate	5, 8, 9
Neocate Junior Vanilla	9	Sodium fusidate [fusidic acid]	5, 6, 8
Neostigmine metilsulfate	13	Sodium nitroprusside	14
Nicotinic acid	15	Sulfadiazine silver	15
Nifedipine.....	10	Sulphadiazine silver.....	15
Nilstat	14	Suxamethonium chloride	13
Nystatin	14	T	
O		Terbinafine	6
Octreotide	13	Testosterone.....	11
Oestriol	15	Testosterone cipionate	6
Olsalazine	10	Testosterone cypionate	6
Oseltamivir.....	13	Travoprost	9
Ovestin	15	Travopt	9
Ozurdex	8	Trimethoprim with sulphamethoxazole [co-trimoxazole].....	16
P		Trisodium citrate	15
Paclitaxel	8, 18	U	
Paclitaxel Ebewe	8, 18	Univent	18
Paracare.....	11	V	
Paracetamol.....	11	Vitamin B6 25.....	5
Pegasys.....	16	Vit.D3	14
Pegasys RBV Combination Pack	16	Z	
Pegylated interferon alfa-2A.....	16	Zanamivir	13
Pemetrexed.....	7	Zinc and castor oil.....	12



Email: enquiry@pharmac.govt.nz

www.pharmac.govt.nz/medicines/hospital-pharmaceuticals

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

ISSN 1179-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand